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ABSTRACT
Hypertension is a major risk factor for the development of cardiovascular complications such as 
atherosclerosis, myocardial infarction, stroke and renal failure. In common to these adverse events 
is the accumulation of connective tissue in the involved structures. The exact mechanisms 
contributing to the regulation of connective tissue homeostasis in hypertension are still obscure. 
Recently an important regulator of the connective tissue synthesis was found, and named 
“connective tissue growth factor” (CTGF). During the recent years accumulating evidence has 
connected CTGF overexpression with various inflammatory and fibrotic diseases. The present 
series of studies were conducted to investigate the role of the CTGF in hypertension-induced end 
organ damage. Special attention was focused on angiotensin II (Ang II), an effector molecule of the 
renin-angiotensin system (RAS), as a regulator of the CTGF gene expression. 
Cyclosporine (CsA)-treated spontaneously hypertensive rats (SHR) on high sodium diet (7-9 weeks 
old) and double transgenic rats harboring human renin and angiotensinogen genes (dTGR) (3-4 
weeks old) were used as hypertensive animal models with increased RAS activity. The roles of the 
blood pressure and Ang II as regulators of the CTGF gene expression were studied. To further 
elucidate the regulatory mechanisms of the CTGF gene, intervention studies with antihypertensive 
drugs (ACE inhibitor enalapril, AT1 receptor antagonist valsartan), immunosuppressives (CsA, 
tacrolimus, everolimus), antioxidant (?-lipoic acid) as well as with magnesium were conducted. 
Blood pressure was recorded, the relative organ weights measured, mediators of inflammation were 
detected with immunohistochemistry and electrophoretic mobility shift assay. Tissue morphology 
was examined and the expression of myocardial and renal CTGF mRNA was determined with in 
situ hybridization, Northern blot and RT-PCR. 
Arterial hypertension induced the expression of the myocardial CTGF mRNA in CsA-treated SHRs. 
The expression of the CTGF gene correlated closely with blood pressure, and was prevented with 
concomitant antihypertensive treatment by RAS antagonists enalapril and valsartan.  
In dTGRs, Ang II induced the expression of the CTGF in a time- and blood pressure-dependent 
manner. This Ang II-induced expression of the CTGF co-located with marked perivascular 
inflammatory response, cellular proliferation, vascular damage, and was associated with the 
activation of the redox-sensitive transcription factors NF-κB and AP-1. 
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The pathological expression of the CTGF in dTGRs was prevented by AT1 receptor antagonist 
valsartan. Suppression of the Ang II-mediated perivascular inflammatory response by an 
antioxidant ?-lipoic acid or calcineurin inhibitors CsA and tacrolimus protected against the 
overexpression of the CTGF in the dTGR. Dietary magnesium supplementation protected against 
the induction of the CTGF gene in the dTGR. Additive therapeutic effects were found with 
magnesium supplementation and tacrolimus treatment.
Taken together, these findings provide evidence that (1) high blood pressure induces the myocardial 
expression of the CTGF gene (2) Ang II induces CTGF gene expression via AT1 receptor in a time- 
and blood pressure-dependent manner (3) oxidative stress induces CTGF expression (4) systemic 
magnesium balance regulates the expression of the CTGF. 
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1 INTRODUCTION
According to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC), high blood pressure is defined as a blood pressure of >140/90 Hg 
(Chobanian et al., 2003). In a great majority of adult patients no identifiable cause for hypertension 
can be found. High blood pressure affects every fourth person in the industrialized countries. The 
correlation between elevated blood pressure and cardiovascular complications has been clearly 
demonstrated (for review, see Staessen et al., 2003). 
Hypertension is among the most important risk factors for the development of several 
cardiovascular diseases (atherosclerosis, coronary artery disease, myocardial infarction, stroke and 
renal failure) (Chobanian et al., 2003) which necessitate a huge burden to medical care and 
expences. The exact mechanisms contributing to the hypertension-induced end organ (blood 
vessels, heart, kidney) damage remain obscure. The prevalence of morbid cardiovascular episodes 
among the treated hypertensive patients remains higher when compared to the normal population 
(for review, see Schiffrin, 2002a). This casts the question about the nature of hypertension-induced 
end organ damage. 
The pathological changes in the heart, blood vessels and kidneys of the hypertensive patients 
include vascular remodeling, inflammation and vast connective tissue accumulation leading to 
scarring of the involved organs (Mezzano et al., 2001; Dostal, 2001; reviewed by Williams, 2001). 
Scarring of the heart or kidneys leads to the deterioration and ultimately to the failure of the organ 
function. The accumulation of connective tissue is controlled by various growth factors. Much 
attention has previously been focused on transforming growth factor β1 (TGFβ1), a regulator of
collagen synthesis (Lijnen et al., 2000). Recently, however, a new growth factor, termed 
“connective tissue growth factor” (CTGF), acting downstream from TGFβ1 was found (for review, 
see Moussad and Brigstock, 2000). The expression of the connective tissue growth factor (CTGF), 
which mediates the TGFβ1-induced collagen synthesis, has been noted to increase in the 
atherosclerotic lesions, myocardial infarctions and renal fibrosis (Oemar et al., 1997; Ito et al., 
1998; Ohnishi et al., 1998). The regulation of the fibrosis-promoting CTGF gene is probably under 
various vasoactive substances, growth factors and locally acting cytokines. 
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Currently, much attention is focused on angiotensin II (Ang II), the effector molecule of the renin-
angiotensin system (RAS). Ang II has an important role in the regulation of blood pressure, 
vascular tone and body fluid balance (Weir and Dzau, 1999). The results of the recent Heart 
Outcomes Prevention Evaluation (HOPE) study and others have shown that antagonizing the action 
of Ang II has important protective effects on cardiovascular system, even independent of blood 
pressure reduction (Yusuf et al., 2000; Schiffrin, 2002a). In addition to its role as a blood pressure 
regulator, Ang II acts also as a growth factor contributing to cardiac hypertrophy and synthesis of 
connective tissue in the heart, kidneys and blood vessels (Dostal, 2001). Ang II has been reported to 
cause local inflammatory response by generating reactive oxygen species (ROS) and promote the 
accumulation of connective tissue via the activation of TGFβ1 (Fakhouri et al., 2001; Sorescu and 
Griendling, 2002). 
The present study was designed to explore the role of the CTGF in the pathogenesis of 
hypertension-induced end organ damage. In particular the influence of blood pressure and Ang II on 
CTGF gene regulation was examined. As Ang II is a known promoter of hypertension and 
cardiovascular complications, we used two hypertensive animal models with increased activity of 
the renin-angiotensin system; namely, cyclosporine-treated spontaneously hypertensive rats (SHR) 
on high sodium diet (Mervaala et al., 1997), and double transgenic rats harboring human renin and 
angiotensinogen genes (dTGR) (Ganten et al., 1992). To further clarify the regulatory mediators of 
the CTGF gene expression; we conducted intervention studies with antihypertensive drugs, 
antioxidant, magnesium supplementation, as well as with anti-inflammatory immunosuppressive 
drugs. 
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2 REVIEW OF THE LITERATURE
2.1 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) 
2.1.1 Structure and physiological functions
The term “connective tissue growth factor” (CTGF) was first introduced in 1991 by Bradham et al. 
to describe a novel growth factor that was secreted by human endothelial cells in culture. 
The CTGF gene belongs to the CCN (acronym of CYR61/CEF-10, CTGF/Fisp-12 and Nov) family 
of growth factors (Moussad and Brigstock, 2000). The gene for human CTGF located in 
chromosome 6q23.1 comprises five exons and four introns and has several regulatory elements such 
as activator protein-1 (AP-1), nuclear factor kappa B (NF-κB), cyclic adenosine monophosphate 
(cAMP), SMAD, and a unique transforming growth factor beta (TGF?)-response element (TβRE) 
in its promoter region (Figure 1) (Martinerie et al., 1992; Grotendorst et al., 1996; for review, see 
Brigstock, 1999; Moussad and Brigstock, 2000). This element is different from the other reported 
TGF?-responsive elements and is not present in other genes regulated by TGF? (Grotendorst et al., 
1996). Prior translation the CTGF mRNA is a target for posttranscriptional regulation by various 
factors (Figure 2). The CTGF is a cysteine-rich peptide with four domains containing 349 amino 
acids and a secretory signal peptide at the N terminus (reviewed in Gupta et al., 2000) (Figure 3). 
The CTGF was first isolated from the endothelial cell culture (Bradham et al., 1991). Subsequently, 
it has been detected in fibroblasts, cartilagenous cells and chondrocytes, cancer cell lines, smooth 
muscle cells, renal podocytes and mesangial cells, hepatic sinusoidal cells, myofibroblasts, 
pancreatic acinar and ductile cells, bronchoalveolar ductile cells, as well as in serum, tear fluid and 
urine (Tamatani et al., 1998; Gupta et al., 2000; Sato et al., 2001; for review, see Blom et al., 2002; 
Riser et al., 2003; van Setten et al., 2003). 
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Figure 1. Genomic structure of the CTGF with hypothesized regulatory elements in the 
                 promoter region (modified from Blom et al., 2002). 
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Figure 2. Organization of the CTGF mRNA with hypothesized regulatory elements in the 
                 untranslated 3’ region (modified from Gupta et al., 2000). 
Figure 3. Modular structure of the CTGF peptide (modified from Gupta et al., 2000). 
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The CTGF participates in several physiological processes including embryonic development and 
differentiation, endochondral ossification, female reproductive tract function in the uterus and 
ovary, wound healing, and angiogenesis (Moussad and Brigstock, 2000; Ivkovic et al., 2003). 
The bioactivity of the CTGF is still under intense research. Depending on the cell types, CTGF has 
been noted to promote mitosis, chemotaxis, stimulate apoptosis, angiogenesis, synthesis of 
collagens, fibronectin and ?5-integrin (Frazier et al., 1996; Gupta et al., 2000). 
The mechanisms by which CTGF exerts its effects on target cells remain more or less unsolved.  
Previous studies have demonstrated that adhesion of the endothelial cells, platelets, and fibroblasts 
to CTGF is mediated through different integrin receptors. In the study by Babic et al. (1999), 
murine CTGF was noted to modulate endothelial cell adhesion, migration, survival and 
angiogenesis via ?5β3 integrin receptor-dependent pathways. In addition, Segarini et al. (2001) 
identified the low density lipoprotein receptor-related protein/?2-macroglobulin receptor (LRP2) as 
a receptor for CTGF in fibroblasts (Schober et al., 2002). By signaling through the integrins, a 
mechanistic interpretation is provided for the chemotactic and mitogenic properties of the CTGF, as 
well as for its functions in extracellular matrix (ECM) remodeling during angiogenesis and wound 
healing (Blom et al., 2002). 
After binding to its receptors, CTGF is presumably internalized into the endosomes, translocated to 
the cytosol, phosphorylated by protein kinase C (PKC) and transported to the nucleus where it 
stimulates the production of RNAs (Wahab et al., 2001). 
2.1.2 Regulation of CTGF expression 
Both in endothelial cells and smooth muscle cells the expression of the CTGF is induced by TGF?1
(Hishikawa et al., 1999). Although several factors are capable of regulating CTGF gene expression, 
it is generally believed that CTGF is transcriptionally activated primarily through TGFβ1. In 
addition to TGFβ1, CTGF gene expression is also regulated by high glucose, tumor necrosis factor 
α (TNFα), vascular endothelial growth factor (VEGF), cortisol, cAMP, coagulation protease 
thrombin, prostaglandin E2 (PGE2), drugs such as iloprost and statins, as well as with 
cytomegalovirus infection (Duncan et al., 1999; Murphy et al., 1999; Ricupero et al., 1999; 
Abraham et al., 2000; Pereira et al., 2000; Suzuma et al., 2000; Howell et al., 2001; Stratton et al., 
2001; Eberlein et al., 2001; Inkinen et al., 2001). Furthermore, it has been recently shown that other 
growth factors such as the platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
and fibroblast growth factor (FGF) also activate CTGF gene expression at a transcriptional level 
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(Brigstock, 1999; Moussad and Brigstock, 2000). The intracellular pathways regulating CTGF are 
still not clear. Very recently, Leask et al. (2003) reported that SMAD, PKC and Ras/MEK/ERK 
(kinase) pathways are necessary for the TGF?1-mediated induction of the CTGF promoter. 
Induction of the CTGF promoter is antagonized by c-Jun or by MEKK1 (kinases), suggesting that a 
proper balance between the Ras/MEK/ERK and JNK MAPK cascades is necessary for the induction 
of the CTGF. Other important regulators of the CTGF might also be NF-κB, AP-1 and reactive 
oxygen species (ROS), which are known mediators of inflammation. ROS stimulates the expression 
of the CTGF through the activation of Janus kinases and AP-1 (Park et al., 2001).The role of the 
NF-κB is more complex as, depending on the cell type, its activation has been shown to induce or 
reduce the expression of CTGF (Blom et al., 2002). Interestingly, it has been previously noted that 
the activity of the CTGF can be induced by varying the amount of tension (cyclic stretch and static 
pressure) imposed on cells (Hishikawa et al., 2001; McCormick et al., 2001). This effect could be 
explained by the presence of a stretch-responsive element in the CTGF promoter, which might 
regulate the activity of the CTGF under conditions of mechanical stress (Blom et al., 2002).  
2.1.3 Role of CTGF in pathological states
As a mediator of fibrotic processes, the expression of the CTGF has been noted to increase in 
several pathological conditions involving inflammation and connective tissue accumulation  
(Table 1). The expression of the CTGF has been reported to be practically absent in normal human 
arteries, but highly enhanced in the intimal smooth muscle cells of atherosclerotic lesions and in the 
myocardial infarcts (Oemar et al., 1997; Ohnishi et al., 1998). In the human kidney, the expression 
of the CTGF has been found to be markedly increased in the glomerular and interstitial 
inflammatory lesions with cellular proliferation and matrix accumulation e.g. IgA nephropathy, 
chronic transplant rejection, crescentic glomerulonephritis, focal glomerulosclerosis, lupus nephritis 
and membranoproliferative glomerulonephritis (Ito et al., 1998). Furthermore, the up-regulation of 
the CTGF has been noted in numerous other pathological states and lesions (scleroderma, keloids, 
dermatofibroma, malignant melanoma and other malignancies, chronic pancreatitis, hepatitis and 
liver cirrhosis, Crohn’s disease and ulcerative colitis, pulmonary fibrosis and sarcoidosis) (Gupta et 
al., 2000). 
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The role of the CTGF in inflammation-wound healing is evident. CTGF mediates the normal scar 
formation in the lesion. Physiologically the activity of TGFβ1 and CTGF diminishes as the wound 
heals and an adequate scar-formation is achieved. However, in pathologic conditions where the 
inflammatory component remains abundant, the expression of the CTGF and hence the production 
of collagens stay elevated. The chronic induction of the CTGF expression results in a pathologic 
fibrosis of the involved organ and development of improper scars, like keloids (Igarashi et al., 
1996). 
Table 1. Enhanced expression of CTGF in different diseases.  
Scleroderma, eosinophilic fascitis, Dupuytren's contracture  Igarashi et al., 1996 
Desmoplastic malignant melanoma Kubo et al., 1998 
Mammary carcinoma Frazier and Grotendorst, 1997 
Chronic pancreatitis di Mola et al., 1999 
Pancreatic cancer Wenger et al., 1999 
Liver fibrosis, hepatitis C Paradis et al., 1999 
Crohn’s disease, ulcerative colitis Dammeier et al., 1998 
Idiopathic pulmonary fibrosis, sarcoidosis, asthma Allen et al., 1999; Burgess et al., 2003 
Atherosclerosis Oemar et al., 1997 
IgA nephropathy, crescentic glomerulonephritis, focal 
glomerulosclerosis, lupus nephritis, membranoproliferative 
glomerulonephritis and diabetic nephropathy  
Ito et al., 1998; Wahab et al., 2001 
Glioblastoma Pan et al., 2002 
Ischaemic heart disease Chen et al., 2000 
Cartilaginous tumors Shakunaga et al., 2000 
Cerebral infarction Schwab et al., 2000 
Disease Reference 
Malignancies 
Renal diseases 
Cardiovascular diseases 
Pulmonary diseases 
Gastro-intestinal diseases 
Dermatological diseases 
Riser et al., 2003 
2.1.4 Therapeutic approaches to prevent CTGF overexpression 
During the last couple of years, accumulating evidence has postulated CTGF as an attractive target 
for antifibrotic therapy. Although anti-TGFβ1 therapy has been shown to suppress the expression of 
the CTGF, it is also pro-carcinogenic and pro-inflammatory in experimental models (Murphy et al., 
1999). Therefore the use of anti-CTGF therapy without dampening the growth-regulating effect of 
TGFβ1 could be appropriate.  
Recently, a neutralizing antibody and an antisense oligonucleotide to CTGF have been developed. 
These molecules have been shown to block the TGF?-stimulated collagen synthesis in various 
preclinical models (Blalock et al., 2003). In clinical use, there are no specific drugs to prevent the 
overexpression of the CTGF. The down-regulation of the CTGF has been noted with drugs having 
diverse actions. Previously, Stratton et al. (2002) have shown that prostacyclin derivatives (iloprost) 
are able to prevent the induction of the CTGF in fibroblasts and in patients with scleroderma 
through the activation of PKA and blockade of the Ras/MEK/ERK signaling. Also, the cholesterol-
lowering drugs 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors (statins) 
have been shown to suppress the expression of the CTGF via inhibition of RhoA (Eberlein et al., 
2001). Moreover, Candido et al. (2002) have demonstrated that angiotensin convertase enzyme 
(ACE) inhibitor therapy inhibits the CTGF overexpression in the aorta of the diabetic 
apolipoprotein E-deficient mice. 
2.2 HYPERTENSION-INDUCED END ORGAN DAMAGE 
2.2.1 Lesions of the heart, vasculature and kidney
Cardiovascular and renal complications associated with hypertension have become one of the major 
risk factors for disability and premature death in the industrialized countries. The hypertensive heart 
diseases (left ventricular hypertrophy (LVH) and dilated cardiomyopathy (DCM)) resulting from 
the hypertrophy of cardiac muscle fibers and/or deposition of extracellular matrix (fibrosis) can lead 
to deterioration of cardiac function and ultimately to morbid and lethal cardiac events. Vascular 
diseases (atherosclerosis and arteriosclerosis), originating from the thickening and stiffening of the 
arteries, lead to hypoperfusion of different organs and can cause sudden death by occlusion of the 
arteries (myocardial infarction, stroke) (for review, see Escobar, 2002). Strokes are strongly 
associated with hypertension as hypertension-associated atheromatous plaques narrow brain 
arteries, predisposing to local clot formation and ischaemia (for review, see Dickinson, 2003). 
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The renal damage, termed benign nephrosclerosis, can be characterized by a decline in arterial, 
tubular and glomerular function (Bohle and Ratschek, 1982). The hypertension-associated renal 
damage can lead to renal dysfunction and worsening of the hypertension. Non-insulin dependent 
diabetes mellitus is the leading cause of end-stage renal disease requiring dialysis or kidney 
transplantation in industrialized countries (Gerth et al., 2002; Keane et al., 2003). Diabetic 
nephropathy with its resultant hypertension has exponentially increased the need and expences of 
medical care in industrialized countries (Gerth et al., 2002; Williams et al., 2002). 
2.2.1.1 Sympathetic nervous system in the pathogenesis of hypertension-induced end organ 
damage
Sympathetic nervous system has a central role in controlling blood pressure and electrolyte balance. 
Besides regulating adrenalin secretion from the adrenals, sympathetic nerves control renal blood 
flow, sodium excretion and renin secretion (for review, see DiBona, 2000). Although the 
importance of sympathetic nervous activation in the pathogenesis of essential hypertension is well 
documented, the exact pathophysiology of the sympathetic nervous dysfunction present remains to 
be elucidated. In addition to the increased rate of sympathetic nerve firing there are several 
explanations for the increased spillover of noradrenaline to plasma, providing a neurogenic basis of 
hypertension (reviewed by Esler et al., 2001). Sympathetic nervous system overactivity is present in 
a proportion of patients with essential hypertension, principally in younger ones with hypertension 
in its developmental phase (Esler et al., 1989). Sympathetic stimuli regulate the volume of 
myocytes, proliferation of smooth muscle cells and ECM production, and thereby contribute to 
cardiac and vascular remodeling (Hu et al., 1999; O’Gallaghan and Williams, 2002; Schlaich et al., 
2003). Previously Aggarwal et al. (2002) have demonstrated an elevated noradrenergic activity in 
human congestive heart failure (CHF) and a positive correlation between this and the level of 
whole-body noradrenaline spillover. Moreover, LVH has been shown to associate with increased 
sympathetic activity largely confined to the heart, suggesting that increased cardiac noradrenaline 
release is related to the development of LVH (Schlaich et al., 2003). As enhanced levels of 
sympathetic activity promote hypertension, cardiac arrhytmias and increased activity of RAS, 
treatment with prazosin, clonidine, ganglionic blockers, reserpine and ?-adrenoceptor blockers have 
been widely used in the treatment of cardiovascular diseases. 
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2.2.1.2 Involvement of the mechanical factors 
Heart and vasculature 
In the heart, arterial hypertension causes myocardial hypertrophy. When enhanced hemodynamic 
load is imposed on the left ventricle for a prolonged time the physical stress results in hypertrophic 
responses such as the activation of the phosphorylation cascades of many protein kinases, 
expression of specific genes and an increase in protein synthesis ultimately leading to the 
impairment of the cardiac function and malignant enlargement of the myocardium (pathological 
hypertrophy) (Wikman-Coffelt et al., 1979). During this pathological process, the production of 
vasoactive peptides such as Ang II, is increased which plays a critical role in the induction of 
cardiohypertrophic responses (for review, see Zou et al., 2002). 
Along with the enlargement of cardiomyocytes, there are alterations in the ECM which provides the 
supportive structure for the myocytes and capillaries (for review, see Weber, 2001). In the process 
of cardiac hypertrophy, fibroblasts enhance their synthesis of fibrillar collagens, which leads to the 
accumulation of collagens in the interstitium, and around the myocardial arteries. Subsequently this 
leads to the stiffening of the myocardium and deterioration of cardiac contractile function (Weber, 
2001). Although it is difficult to separate the effects of mechanical and hormonal stimuli, in vitro
studies support a role for mechanical stress in regulating the cardiac hypertrophy. It has been 
previously shown that the stretching of the muscle fibre leads to enhanced synthesis of contractile 
proteins (Wikman-Coffelt et al., 1979). Even the stretch directed towards a single cardiac cell 
evokes the activation of hypertrophy-associated genes (c-fos, c-jun, c-myc, ?-actin, β-myosin) 
(Sadoshima et al., 1992). Besides the genes associated with cardiomyocyte hypertrophy, the 
synthesis of cardiac collagens and eventually cardiac fibrosis is also regulated by mechanical 
stimuli (Carver et al., 1991). 
Increased wall tension due to pressure overload serves as a growth promoting stimulus for smooth 
muscle cells (VSMC) within the vessel wall. This leads to the proliferation and hypertrophy of the 
VSMC. In addition, activated smooth muscle cells secrete components of the ECM (collagens) 
(Sumpio et al., 1988). Together with the concomitant endothelial dysfunction this leads to the 
stiffening of the arterial structure, increased peripheral resistance and weakened responsiveness to 
vasorelaxing factors (arteriosclerotic changes) (Shepherd, 1990; reviewed by Jeffery and Morrell, 
2002). 
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Kidney
The importance of the kidneys in regulating blood pressure was comprehensively reviewed in 1972 
by Guyton et al.. Kidneys regulate blood pressure and systemic sodium and fluid balance via the 
action of renin, Ang II, aldosterone and vasopressin. A high intake of sodium can promote “salt-
sensitive” hypertension and it has been previously shown that a high sodium intake predicts 
mortality and risk of coronary heart disease, independent of other cardiovascular risk factors, 
including blood pressure (Tuomilehto et al., 2001). As the kidneys have a sophisticated auto-
regulatory system for the adjustment of the intrarenal blood flow, it seems probable that the renal 
lesions accompanying hypertension are not a direct consequence from the pressure overload. 
Instead the increased renal vascular resistance seems to be present already at the early stages of 
hypertension (reviewed by Ruilope et al., 1994). Therefore, it seems possible that in humans, 
arterial hypertension may sometimes be a consequence from the alterations in the renal circulation 
or nephron number (Keller et al., 2003). Support to this notion comes from the transplantation 
studies, where the “hypertensive kidney” has been transplanted into normotensive animals which 
thereafter become hypertensive (Dahl and Heine, 1975).  
2.2.1.3 Involvement of the hormonal factors and inflammation 
The prevalence of pressure-overload cannot solely explain the occurrence of organ lesions in the 
hypertensive patients, as the frequency of morbid cardiovascular episodes among the treated 
hypertensive patients remains higher when compared to the normal population. Recently, much 
attention has been focused on the hormonal mechanisms in the development of the end organ 
damage. With ever-increasing data from numerous studies, hormonal factors and inflammatory 
reactions are today considered as the key effectors in contributing to the development of 
myocardial, vascular and renal lesions associated with hypertension (Figure 4) (Ridker et al., 1997; 
for review, see Lagrand et al., 1999). Very recently, in the Framingham study, it was shown that 
increases in the serum inflammatory markers, particularly elevated interleukin-6, were associated 
with increased risk of congestive heart failure in a patient population without prior myocardial 
infarction (Vasan et al., 2003). 
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Figure 4. Simplified scheme of events leading from vascular injury to fibrosis 
                (modified from Franklin, 1997).
Heart and vasculature 
The most common injury to the heart is the myocardial infarction. During the first weeks after a 
massive infarction, the myocardium is susceptible to rupture. The function of the repair process is to 
maintain the structural integrity. The replacement of the contractile tissue by scar leads to impaired 
myocardial function by decreasing the myocardial contractility. In hypertensive heart disease, 
resistance arteries (including coronary vessels) undergo remodeling processes. Coronary arteries 
develop accumulation of collagen in the adventitial layer (perivascular fibrosis) where bundles of 
collagen extend also into the interstitial areas of the myocardium (interstitial fibrosis) (Silver et al., 
1990). The atherosclerotic lesions develop within several years and are characterized by smooth  
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muscle cell proliferation, chronic inflammatory reaction and deposition of lipid and matrix in the 
subintimal space. 
Kidney 
Depending on the nature of the lesion, the healing process in the kidney results in fibrosis of the 
affected glomeruli and interstitium. The hypertension-associated lesions usually comprise damage 
to the afferent arteries with the thickening of the medial layer with connective tissue. In more severe 
cases the afferent arteries have marked concentric hypertrophy and/or fibrinoid necrosis. In 
association with arterial damage there is often glomerular (glomerular ischaemia, 
glomerulosclerosis) and tubular (tubulo-interstitial fibrosis) lesions (Bohle and Ratschek, 1982). 
The inflammation-healing process 
The repair process of the affected organ begins immediately after injury and thus overlaps with the 
inflammatory response. It is through continuum of inflammatory reactions and deposition of ECM 
that the injuries are healed. The connection between inflammation and fibrosis can be seen in the 
early phases of embryonic development when there is no inflammatory response to an injuring 
stimulus. The healing occurs by proliferation of the cells surrounding the lesion and no fibrosis 
occurs. 
Whether the injuring stimulus has been a myocardial infarction following a coronary artery 
occlusion or an effect by an endogenous hormone, the healing process eventuates in fibrous tissue 
formation (Figure 4). On the first stage of the inflammatory phase, platelet-derived cytokines 
attract cells from the leukocyte axis and polymorphonuclear neutrophilic leukocytes (PMN) 
infiltrate the lesion. These cells appear within hours from the injury and their function is to remove 
the cellular debris from the wound. The infiltration of PMN is soon followed by the accumulation 
of monocytes/macrophages which remove debris from the lesion and release pro-inflammatory 
cytokines and interleukins; colony-stimulating factors (GM-CSF), growth factors (TGFβ1, 
thrombospondin-1 (TSP-1), PDGF, FGF) and ROS. Lymphocytes possess the ability for antigen-
specific recognition and they control the function of other leukocytes. B lymphocytes participate in 
the humoral response by secreting various antibodies and T lymphocytes, in turn, regulate the 
cellular inflammatory response. In addition to the cells specific to the injured tissue, the stromal 
cells (fibroblasts, smooth muscle cells, endothelial cells and inflammatory cells) have a major role 
in repair. In response to growth factors released by other cells, fibroblasts begin to proliferate and 
secrete components of the ECM. The fibroblast-derived collagens assemble to form the fibrillar 
network that eventually becomes the scar of the damaged area. 
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2.2.1.3.1 Angiotensin II 
From the large number of growth factors involved in the regulation of inflammation and 
regeneration, much attention has recently been paid on Ang II. 
Ang II is the active effector of the RAS. Ang II regulates blood pressure, plasma volume and the 
activity of the sympathetic nervous system. It has also a fundamental role as a growth factor in 
myocardial, vascular and renal remodeling (for review, see Touyz and Schiffrin, 2000). Originally 
described as a systemic humoral system, Ang II is currently known to be produced also in several 
tissues by the activation of local RAS (for review, see Bader et al., 2001). Under conditions of salt 
or volume depletion or sympathetic activation, the protease renin, derived from the macula densa of 
the juxtaglomerular apparatus, cleaves the liver-derived peptide angiotensinogen to form 
angiotensin I (Ang I). The main effector of the RAS, Ang II, is then formed by the ACE. ACE 
exists usually in an endothelium-bound form with particularly high concentrations in the lung 
(Bader et al., 2001). In addition to ACE, Ang II can be formed by other enzymes. Generation of 
Ang II has been noted to occur via the activation of chymase, cathepsin G and tonin (reviewed by 
Dzau et al., 1993). Local (tissue) RAS is activated under pathophysiological conditions where the 
synthesized Ang II appears to contribute to altered tissue function and morphology (Hirsch et al., 
1990). Furthermore, in some tissues, locally formed Ang II may exceed the importance of 
circulating Ang II (Navar et al., 1996). Ang II exerts its effects via binding to its receptors located 
in the cell surface. Two main subtypes of Ang II receptors have been cloned, described and 
classified, namely the G-protein-coupled AT1 and AT2 receptors (Timmermans et al., 1993). Two 
other subtypes of Ang II receptors have also been described but are not yet included in the 
definitive classification of the mammalian AT receptors. To date, AT1 receptors have been shown to 
mediate most of the physiological actions of Ang II, and this subtype is predominant in the control 
of Ang II-induced vascular functions (Touyz and Schiffrin, 2000). In contrast to the AT1 receptor, 
the physiological role of the AT2 receptor remains elusive. It has been suggested that the AT2
receptor counteracts the Ang II-induced effects of the AT1 receptor (Nakajima et al., 1995; 
reviewed by Siragy and Carey, 2001). Although the main function of smooth muscle cells is 
vasoconstriction, it has also become evident that the Ang II-induced stimulation of the AT1
receptors has a major role in the proliferation of VSMC and fibroblasts, deposition of ECM and 
inflammation (Dostal, 2001; Mezzano et al., 2001). 
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Signaling events generated by Ang II 
Upon binding to its receptor, Ang II causes an increase in the intracellular free Ca2+, Na+ and an 
efflux of Mg2+ (Touyz and Schiffrin, 2000). Ang II activates growth promoting signal pathways 
(Janus kinases, MAP-kinases, calcineurin and p70S6-kinase) and mediators of cell migration (focal 
adhesion kinase) and regulators of ROS and inflammation (nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidases, NF-κB, AP-1) (Schmelzle and Hall, 2000; Molkentin and Dorn, 
2001; Liu et al., 2003). The Ang II-mediated activation of intracellular kinases leads to the 
induction of early growth-response genes and regulation of the vascular and cardiac growth, 
remodeling and repair (reviewed by Berk and Corson, 1997). 
The calcium-calmodulin, Ser/Thr protein phosphatase calcineurin and its downstream 
transcriptional effector nuclear factor of activated T cells (NFAT) play pivotal roles in the immune 
response. Activation of calcineurin leads to dephosphorylation and nuclear translocation of NFAT 
and regulation of several inducible genes in T cells. Recently, a role for calcineurin-dependent 
pathways in the signal transduction of cardiac growth has been postulated. Stimulation of 
calcineurin is capable of driving cardiac hypertrophy, heart failure, and death in experimental 
animal models (Molkentin et al., 1998; reviewed by Molkentin, 2001). Ang II stimulates the 
hypertrophy and proliferation of cardiomyocytes and cardiofibroblasts through the induction of 
calcineurin thus suggesting a role for calcineurin-dependent pathways in the pathogenesis of Ang 
II-induced cellular hypertrophy and proliferation (Fu et al., 1999). 
Previous studies have provided compelling evidence that Ang II controls the process of cardiac and 
vascular hypertrophy also via AT1 receptor-mediated activation of p70S6-kinase which regulates 
the cellular response to nutrients, organization of the actin cytoskeleton, membrane traffic, protein 
degradation, PKC signaling, ribosome synthesis and possibly, mechanisms of cancer (reviewed in, 
Schmelzle and Hall, 2000). In addition, p70S6-kinase has a central role in inflammatory reactions 
(Giasson and Meloche, 1995; Takano et al., 1996; Lehman et al., 2003). 
Ang II and inflammation
A link between the RAS and inflammation-wound healing has been previously noted. Ang II 
stimulates the proliferation of lymphocytes and regulates their activation through AT1 receptor-
mediated induction of calcineurin phosphatase (Nataraj et al., 1999). Chronic activation of RAS, 
resulting in a permanent elevation in plasma and tissue Ang II, leads to perivascular inflammation 
and fibrosis, vascular remodeling, myocyte necrosis and subsequent scar formation, even in the 
absence of hypertension (Figure 5) (Ratajska et al., 1994; Mervaala et al., 1999; Weber, 2001). 
Ang II stimulates NADPH oxidase to produce ROS such as superoxide anions and hydrogen  
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peroxide, which participate in the regulation of VSMC growth, apoptosis of cardiomyocytes, 
induction of vascular inflammatory response, impairment of endothelial-dependent vascular 
relaxation, atherosclerosis and pathogenesis of mechanical stress-induced cardiac hypertrophy 
(Figure 5) (Aikawa et al., 2001; Aikawa et al., 2002, reviewed by Griendling et al., 2000). Our 
group has previously shown that Ang II-mediated inflammatory reaction in the heart, kidney and 
vasculature, characterized by leukocyte infiltration and vascular adhesion molecule overexpression 
are due to Ang II-induced ROS formation and activation of the redox-sensitive transcription factors 
NF-κB and AP-1 (Müller et al., 2000a). Moreover, we have shown that Ang II controls the 
migration of mature dendritic cells even by blood pressure-independent mechanisms and activates 
monocytes/macrophages even in the uninjured areas (Mervaala et al., 1999; Müller et al., 2002). 
Figure 5. Different mechanisms of Ang II-induced vascular inflammation  
                (modified from Ruiz-Ortega et al., 2001) 
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Ang II-mediated induction of growth factors
Ang II has a major role in regulating the cardiac and renal growth and structure. In addition to the 
pressure-induced mechanical factors, hypertrophy of the heart is also governed by the growth-
promoting action of Ang II. Similarly, a number of kidney diseases, and their progression to the 
end-stage renal disease, are driven, in part, by the effects of Ang II. Ang II is a powerful mitogen 
and an ECM promoting factor for many cell types. It increases DNA synthesis, promotes cell-cycle 
progression and up-regulates the expression of growth factors such as endothelin-1, TGFβ1, PDGF, 
and FGF which induce cellular hypertrophy, hyperplasia and production of the ECM (Stirling et al., 
1990; Gibbons et al., 1992; Nakahara et al., 1992; Kaiura et al., 2000). The Ang II mediated 
production of collagen and fibronectin in the heart and kidney is primarily mediated by TGF?1
(Kagami et al., 1994; Everett et al., 1994; Funck et al., 1997). 
TGFβ is one of the most potent profibrotic stimuli to fibroblasts. TGF? participates in the normal 
development, wound repair, and several pathological processes including cardiac, renal and liver 
fibrosis, development of atherosclerosis, and arteriosclerosis (for review, see Border and Noble, 
1994; Ihn, 2002). At the site of tissue injury, TGF? (released from infiltrating lymphocytes, 
platelets, activated macrophages, injured myocytes and fibroblasts) is first secreted in a latent form. 
The latent form is then activated by other peptides, such as TSP-1. Activation of the TGF?1
increases the expression of collagen types I, III, VI, VII and X and fibronectin (for reviews, see 
Massague, 1990; Govinden and Bhoola, 2003). The production of the ECM is further enhanced by 
the inhibitory effect of the TGF? on matrix degradation by decreasing synthesis of proteases and 
increasing levels of protease inhibitors (Massague, 1990; Govinden and Bhoola, 2003). The 
functional importance of the TGF? in wound healing can be seen after myocardial infarction. 
Weeks after infarction the TGF? receptor density is markedly increased in both the infarcted and 
noninfarcted myocardium and it is anatomically coincident with sites of fibrosis (Sun et al., 1998). 
Besides participating in the reparative wound healing response, TGF? also controls the fibrosis 
caused by myocardial pressure-overload. As Ang II is known to cause mechanical stress 
(hypertension), fibrosis via the activation of the TGF?1, perivascular inflammation, inflammatory 
end organ damage characterized by an abundance of leukocytes and activation of the inflammatory 
mediators (NF-κB, AP-1), the involvement of Ang II in regulating the expression of the CTGF 
deserves further notice. 
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2.3 ANIMAL MODELS USED IN THE PRESENT STUDY
2.3.1 Spontaneously hypertensive rat (SHR) (Study I)
The SHR is the most widely used animal model for human hypertension. In the SHR the arterial 
hypertension and essential human hypertension share many similarities in the pathogenic 
mechanisms (Trippodo and Frohlich, 1981). The SHR strain was developed in 1963 by Okamoto 
and Aoki. The SHR has been shown to possess a genetic susceptibility to (salt-sensitive) 
hypertension (St. Lezin et al., 1997). Blood pressure in the SHR rapidly increases during the first 3-
4 postnatal months after which it stabilizes at an elevated level. The SHR has an enhanced 
sympatho-adrenal drive and develop functional and structural vascular lesions (impaired 
vasodilatation, vascular remodeling) (Trippodo and Frohlich, 1981; Koller and Huang, 1994). To 
examine the pathogenesis of the CsA-induced hypertension and end organ damage, we have 
developed an animal model, i.e. the CsA-treated SHR on high sodium diet in which magnesium 
deficiency as well as increased RAS activity is involved in the pathogenesis of the CsA toxicity 
(Mervaala et al., 1997; Lassila et al., 2000). 
2.3.2 Double transgenic rat harboring human renin and angiotensinogen genes (dTGR)  
        (Study II, III, IV) 
The transgenic rat-strain carrying the human angiotensinogen TGR-(hAOGEN) and human renin 
TGR-(hREN) genes was originally developed for the study of human renin inhibitors which 
ordinarily do not function in rats. The human components of the RAS in the dTGR do not interact 
with the endogenous rat RAS (Ganten et al., 1992; Bohlender et al., 1997). Hypertension, vascular 
inflammation and end organ damage in the dTGR are due to increased Ang II synthesis by the 
human components of the RAS. The development of the myocardial, renal, and vascular damage in 
the dTGR is age-dependent. In fact, immediately after weaning at the age of 3-4 weeks, myocardial 
and renal tissue morphology, assessed by light microscopy, are indistinguishable between the dTGR 
and the normotensive SD rat. In contrast, marked inflammatory cell recruitment, mainly consisting 
of monocytes and macrophages, as well as an up-regulation of the intercellular adhesion molecule-1 
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and the exctracellular matrix component 
fibronectin, are already present at an early age of the dTGR (Mervaala et al., 1999; Müller et al., 
2000b). These findings have been interpreted as follows: Ang II triggers inflammatory response and  
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exerts direct pro-inflammatory effects by blood pressure-independent mechanisms related to the 
activation of the redox-sensitive transcription factors NF-κB and AP-1 as well as oxidative stress 
(Müller et al., 2002). 
2.4 COMPOUNDS USED IN THE PRESENT STUDY
2.4.1 Enalapril (Study I)
ACE inhibitors are nowadays widely used in the treatment of essential and renovascular 
hypertension. Numerous large clinical studies have shown long-term reductions in the incidence of 
the myocardial infarction, stroke, cardiac arrest, heart failure, and atherosclerosis in patients treated 
with ACE inhibitors (Sleight, 2002). 
ACE inhibitors prevent the ACE-mediated conversion of angiotensin I to angiotensin II. Thus, 
inhibition of the ACE diminishes the formation of Ang II. This in turn, leads to vasodilatation and a 
decrease in blood pressure. In addition, the blockade of the ACE promotes the bioavailability of 
vasodilatating substance bradykinin. As Ang II is an important regulator of renal blood flow, 
sodium homeostasis and mineralocorticoid aldosterone, the ACE inhibition promotes natriuresis by 
increasing renal blood flow, sodium excretion and by preventing the action of aldosterone. In 
addition to the antihypertensive effect, ACE inhibitors have been shown to diminish the 
inflammatory response associated with the end organ damage. Therefore ACE inhibitors are also 
used to prevent the progressive cardiovascular and renal damage in diabetes mellitus. The most 
common adverse effects of the ACE inhibitors: dizziness, headache and cough are usually well 
tolerated (Gradman et al., 1995). 
2.4.2 Valsartan (Study I, II)
Valsartan belongs to the family of the Ang II receptor AT1-antagonists. AT1 receptor antagonists 
are currently used in the treatment of essential hypertension. In clinical trials, valsartan has been 
shown to reduce symptoms, enhance the quality of life and lessen morbidity and mortality in 
patients (for review, see Manohar and Pina, 2003). In patients who cannot tolerate ACE inhibitors 
because of angioedema or severe cough, an AT1 receptor antagonist can be succesfully used as an 
alternative. Recently, valsartan has been approved as a treatment of heart failure in patients who 
cannot be maintained on an ACE inhibitor therapy (Manohar and Pina, 2003). 
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The antihypertensive and anti-inflammatory effects of valsartan resemble closely the ones seen with 
the ACE inhibitor enalapril. By specifically blocking the AT1 receptor, valsartan does not directly 
affect the synthesis of Ang II. In contrast, it prevents the action of Ang II at the receptor level. As it 
has been hypothesized that the AT2 receptor-mediated action of Ang II could have some beneficial 
effects, including anti-fibrotic action, the blockade of only one subtype (AT1) of the Ang II 
receptors might have additional therapeutic effects. The most common adverse effects associated 
with valsartan therapy include: headache, dizziness and tiredness. As the RAS plays a crucial role in 
the normal renal development neither the ACE inhibitors nor the AT1 receptor blockers can be used 
during gestation (for review, see Guron and Friberg, 2000). 
2.4.3 ?-Lipoic acid (Study III) 
In humans, lipoic acid is currently used to improve the glucose effectiveness, and to prevent the 
progression of diabetic neuropathy. Its efficacy has also been examined in the treatment of various 
neurological disorders (for review, see Ziegler et al., 1999). Lipoic acid is a sulfur-containing 
coenzyme required for the mitochondrial dehydrogenase reactions leading to the ATP formation. 
Lipoic acid and the reduced form, dihydrolipoate, are potent natural antioxidants. Lipoic acid reacts 
with superoxide, hydroxyl radicals, hypochlorous acid, peroxyl radicals, and singlet oxygen 
(Carreau, 1979; Packer et al., 1995; Moini et al., 2002). It has been previously reported that dietary 
lipoic acid supplementation decreases oxidative stress, ameliorates hypertension and protects 
against renal and vascular injuries in various animal models (Kocak et al., 2000; Suh et al., 2001). 
Treatment with lipoic acid is usually well tolerated without any major adverse effects (Evans et al., 
2002). 
2.4.4 Cyclosporine A (CsA) (Study I, II) 
The calcineurin inhibitor CsA is a fungal cyclic polypeptide, which has been widely used to prevent 
rejection of organ transplants. After its introduction, CsA has increased graft survival and decreased 
patient mortality significantly compared to more conventional immunosuppressives (Merion et al., 
1984). Moreover, the use of CsA to treat several autoimmune diseases has increased during the 
recent years. 
CsA was the first T lymphocyte selective drug to inhibit lymphocyte function without concomitant 
myelosuppression. CsA binds to cyclophilin to inhibit the phosphatase calcineurin, and thereby 
prevents the dephosphorylation of NFAT and production of inflammatory cytokines, particularly 
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interleukin-2 (IL-2), which is critical for T lymphocyte proliferation and maturation, and interferon 
γ (IFN γ) which is critical for macrophage activation (Liu et al., 1992). 
Despite its beneficial effect on the long-term graft survival, the mortality due to cardiovascular 
diseases and renal failure is greater among the CsA-treated graft recipients than among the normal 
population. This is probably a consequence of the severe and common adverse effects of the CsA, 
hypertension and nephrotoxicity which could be mediated by the CsA-induced activation of RAS 
(Julien et al., 1993; for review, see Textor et al., 1994). 
2.4.5 Tacrolimus (FK506) (Study IV)
The calcineurin inhibitor tacrolimus is a macrolide which effectively prevents rejection of
organ transplants with a concomitant decrease in patient morbidity and mortality (Margreiter, 
2002). 
Similarly to CsA, tacrolimus also inhibits the activity of calcineurin and NFAT and hinders the 
production of inflammatory cytokines IL-2 and IFN γ. Although this occurs via different pathways 
(CsA binds to cyclophilin and tacrolimus binds to FK506 binding protein (FKBP)), the inhibition of
calcineurin produces similar pharmacologic effects with both drugs. Clinical studies suggest similar 
graft and patient survival with either CsA or tacrolimus. The relative frequency of chronic rejection 
in patients treated with tacrolimus versus CsA has not been shown to differ. The side-effect profile 
of CsA and tacrolimus are more or less similar. However, certain side-effects, such as gingival 
hyperplasia, hirsutism, hyperlipidemia and hypertension are more commonly noted with CsA, 
whereas tremor and glucose intolerance are associated more often with tacrolimus (for review, see 
Morales et al., 2001; Hood, 2002). 
2.4.6 Everolimus (SDZ RAD) (Study II) 
The mammalian target of rapamycin (mTOR) inhibitor everolimus is a macrolide 
immunosuppressant used to prevent the inflammatory graft-rejection among the organ transplant 
recipients. It has been used alone and, more commonly, with calcineurin inhibitors. The synergistic 
effect of the everolimus and calcineurin inhibitors have shown low rates of acute rejection, 
improved rates of patient and graft survival, and better renal function in organ transplant recipients 
(for review, see Nashan, 2002a). 
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Everolimus is a proliferation signal inhibitor that blocks growth factor-driven proliferation of the T 
cells, B cells and VSMC by inhibiting the activation of the p70S6-kinase. Everolimus has been 
shown to reduce acute rejection, limit the CsA-induced nephrotoxicity, protect against 
cytomegalovirus infections, and inhibit vascular remodeling (for review, see Nashan, 2001; Nashan, 
2002b). Previous studies have provided strong evidence that the p70S6-kinase plays an important 
role also in Ang II-induced protein synthesis, vascular and cardiac hypertrophy, and possibly, 
inflammatory response (Giasson and Meloche, 1995; Takano et al., 1996). The most common 
adverse effects of the everolimus are thrombocytopenia and hyperlipidemia but not hypertension.  
2.4.7 Magnesium (Study IV) 
In epidemiological studies, altered magnesium balance has been linked to the prevalence of 
hypertension and hypertensive heart diseases. Some subgroups of hypertensive patients (e.g. 
African-Americans, the elderly, patients with insulin resistance or pre-eclampsia) have a high 
incidence of altered magnesium metabolism and pre-eclamptic and eclamptic patients are 
consistently treated with magnesium (Touyz et al., 1987; Touyz et al., 1992; Touyz, 2003). In 
addition, a relationship has been noted between Ang II, magnesium and blood pressure (Touyz and 
Schiffrin, 2000). Magnesium has a multitude of functions in the cardiovascular system. Magnesium 
regulates contractile proteins, transport of other cations (calcium, sodium and potassium), DNA and 
protein synthesis, cell replication, and oxidative-phosphorylation (Touyz, 2003). Serum magnesium 
is regulated within a range of 0.7-1.1 mmol/l, and the current recommended daily allowance (RDA) 
for magnesium is 400mg/d (National Public Health Institute, Finland, 1998). 
In experimental models of hypertension, hypomagnesemia causes elevation in blood pressure and 
increased reactivity to vasoconstrictors (Miyagawa et al., 2000). Thus, it may be possible that Ang 
II-dependent hypertension is associated with cardiovascular effects of hypomagnesemia. It has been 
recently demonstrated that Ang II promotes magnesium efflux and decreases intracellular and 
serum magnesium possibly by stimulating the Na+/Mg2+ exchanger in VSMC. In addition, 
imipramine and quinidine, inhibitors of Na+/Mg2+ exchanger have been shown to attenuate the Ang 
II–induced hypertension in rats (Touyz and Yao, 2003). 
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3 AIMS OF THE STUDY
Since its discovery in 1991, CTGF has received growing attention as a mediator of fibrotic 
processes. Intense research by various groups has provided much information about the regulation 
and nature of the CTGF. The enhanced expression of the CTGF has been linked to several diseases 
associated with inflammation and connective tissue accumulation. However, the role of the CTGF 
in the pathogenesis of the hypertension-induced end organ damage and its connections to RAS has 
not yet been established. 
By using CsA-treated SHR on high sodium diet and dTGR as experimental animal models, 
the specific aims of the study were: 
• To investigate whether the arterial hypertension promotes myocardial
CTGF gene expression. 
• To examine whether Ang II regulates CTGF gene expression. 
• To evaluate whether the antagonists of the RAS protect against the induction of the CTGF. 
• To investigate the effects of immunosuppression and antioxidant therapy on the CTGF gene 
expression. 
• To examine whether magnesium supplementation ameliorates Ang II-induced myocardial 
damage and CTGF overexpression. 
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4 MATERIALS AND METHODS
4.1 EXPERIMENTAL ANIMALS 
In Study I, 48 male spontaneously hypertensive rats (SHR) and 8 Wistar-Kyoto (WKY) rats (Harlan 
Sprague Dawley, Indianapolis, IN, USA) aged 7-9 weeks at the beginning of the experiment were 
used.  
Studies II, III, and IV included 120 male 3-4 week-old double transgenic rats harboring human 
renin and angiotensinogen genes (dTGR) (RCC, Füllinsdorf, Switzerland) and 40 age-matched 
normotensive Sprague Dawley rats (SD) (M&B, Ejby, Denmark). 
The rats were housed in a standard laboratory facility (temperature 22-24°C, a 12-hour light-dark 
cycle). The rats had free access to tap water and feed during the experiment. 
4.2 EXPERIMENTAL DIETS AND DRUG TREATMENTS 
In Study I, rats were placed on high-sodium diet during the treatment (sodium 2.6%, magnesium 
0.2%, potassium 0.8%, calcium 1.0%, phosphorous 0.75%) The food was prepared by adding 
sodium chloride to the commercially available rat chow (R36, Finnewos Aqua, Helsinki, Finland).
In Studies I-IV, enalapril (30 mg/kg/d. Leiras Ltd, Turku, Finland), valsartan (3 and 30 mg/kg/d. 
Novartis Ltd, Basel, Switzerland), ?-lipoic acid (350 mg/kg/d. Sigma Aldrich Finland, Helsinki, 
Finland), and magnesium (0.6 % of the dry weight of the feed) were mixed in the standard food to 
produce the planned daily doses. Normal rat chow served as the control diet. Drug concentration in 
the chow was calculated based on the fact that food consumption of an adult rat is approximately 
20-25 g/day. The actual intake of drugs was verified in the metabolic studies. 
Cyclosporine (2 and 5 mg/kg/d. Novartis Ltd, Basel, Switzerland) and tacrolimus (1 mg/kg/d. 
Fujisawa Europe, Munich, Germany) were administered subcutaneously (I, II, IV). Everolimus (2.5 
mg/kg/d. Novartis Ltd, Basel, Switzerland) was administered by gavage (II). 
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4.3 MEASUREMENT OF BLOOD PRESSURE 
Systolic blood pressure and heart rate from the pretrained rats were measured by using a tail-cuff 
blood pressure analyzer (Apollo-2AB Blood Pressure Analyzer, Model 179-2AB, IITC Life 
Science, Woodland Hills. CA., USA). Before the measurement, the rats were kept at +30°C for 30 
min to enable the pulsations of the tail artery to be detected. Systolic blood pressure was calculated 
from the arithmetic mean of three consecutive results without disturbances in the signal. 
4.4 METABOLIC STUDIES
During the last week of the experiments (I, III, IV) (weekly in Study II), the rats were housed 
individually in metabolic cages. The consumption of food and water was measured, and the 
estimated intake of drugs was calculated. Urine was collected over a 24-hour period, urine volumes 
were measured and samples stored at -80°C until the biochemical determinations were performed. 
4.5 COLLECTION OF THE SAMPLES
At the end of the experiments, the rats were made unconscious with CO2/O2 (70%/30%; AGA, 
Riihimäki, Finland) and decapitated. In Study II, an additional group of SD rats was sacrificed at 
the age of 4 weeks, and dTGR rats at the age of 4, and 5.5 weeks. 
Blood samples were taken into chilled tubes with or without an anticoagulant (EDTA 4.5 mM). 
Plasma and serum were stored at -80°C until the biochemical determinations were performed. The 
heart and kidneys (I-IV) and pulmonary artery (II) were excised, washed with ice-cold saline, 
blotted dry and weighed. Tissue samples for mRNA detection were snap-frozen in liquid nitrogen 
and samples for immunohistochemistry in isopentane (-35°C), then all were stored at -80°C until 
assayed. Samples for conventional morphology, immunohistochemistry and in situ hybridization 
were fixed with 10 % formaline and processed in paraffin with routine techniques.  
4.6 HISTOLOGY 
4.6.1 Sample preparation
The samples for histology were fixed with 10 % formaline for 24-48 hours and processed in 
paraffin through ascending ethanol concentrations and xylene. Sections (3-5 ?m) were cut with  
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a microtome, rehydrated through xylene and descending ethanol concentrations. The sections were 
then stained with Masson’s trichrome and examined under a conventional light microscope without 
knowledge of the sample identity. 
4.6.2 Tissue morphology and scoring of the samples
In the heart, the arteries and ventricular fibrous tissue formation were evaluated. Each sample was 
scored from 0 to 3 (I, III) or from 0 to 4 (II, IV) according to the morphological changes. 
Furthermore, in the kidneys, interstitial, tubular and glomerular changes were evaluated. The 
samples were scored from 0 to 4 (II-IV) according to the morphological changes. Thereafter, the 
damage score was calculated from the arithmetic mean of each group (n=4-10). 
4.7 DETECTION OF mRNA FOR CTGF, COLLAGENS I AND III, AND TGFβ1
4.7.1 In situ hybridization
cDNA clones specific for human CTGF mRNA (1.1kb in pRc/CMV, provided kindly by G. 
Grotendorst, University of Miami, USA) (Study I, II, IV), rat proα1 I collagen mRNA (α1 R2) and 
proα1 III collagen mRNA (pRGR5) (Study I-II); rat TGFβ1 mRNA (Study II) were used for the 
hybridization. The plasmids containing the inserted probe were linearized with restriction enzymes 
to allow transcription of digoxigenin-labeled sense and antisense RNA probes according to the 
Riboprobe Synthesis Kit method (Boehringer Mannheim, Mannheim, Germany). The paraffin 
sections (5 µm) of the heart (Study I-IV), kidney (Study II) and pulmonary artery (Study II) were 
placed onto Superfrost (Menzel-Gläser, Braunschweig, Germany) slides. The sections were 
deparaffinized and hydrated through descending ethanol concentrations. Pretreatment included 
incubation with 10 µg/ml proteinase K and 4 % paraformaldehyde post-fixation. The sections were 
hybridized with labeled RNA-probe in the concentration of 1ng/µl at +50oC for 18 h. The slides 
were washed under stringent conditions including treatment with RNAse A. Digoxigenin-labeled 
probes were detected following the methods from the DIG-detection kit (Boehringer Mannheim, 
antibody dilution 1:2000). After a 16-hour colour substrate incubation the slides were 
counterstained with hematoxylin and coverslipped with aqueous-based mounting medium. Staining 
was accepted positive when seen with the antisense probe only. 
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4.7.2 Northern blot 
RNA extraction 
Total RNA was extracted from the heart (Study I, II, IV) and kidney (Study II) by using the method 
of Chomczynski and Sacchi (1987) and the RNA content was determined spectrophotometrically at 
wavelengths 260 nm and 280 nm. Aliquots of the total RNA were size-separated by electrophoresis 
on agarose gels. After the integrity and uniform loading of the gels were confirmed with ethium 
bromide staining, the RNA was transferred from the gels to nylon membranes by blotting 
(MagnaGraph Nylon Transfer Membrane; Micron Separations Inc., Westborough, MA, USA. 
PosiBlot, Stratagene, La Jolla, CA, USA). The membranes were placed on filter papers, dried, UV-
crosslinked (Spectrolinker, Spectronics Corporation, Westbury, NY, USA) and stored at +4°C until 
hybridization. 
Labeling of the probe
The PCR amplified cDNA clones for human CTGF mRNA 1.1kb in pRc/CMV (Study I, II, IV), rat 
proα1 I collagen mRNA (α1 R2) and rat proα1 III collagen mRNA (pRGR5) (Study I, II), rat TGFβ1
mRNA (Study II), and rat GAPDH mRNA (I, II, IV) as a reference probe were labeled with (32P)dCTP
by random priming (High Prime DNA labeling kit, Boehringer Mannheim). The unincorporated 
label was separated with elution (NICK Column, Amersham Pharmacia Biotech AB, Uppsala, 
Sweden). 
Hybridization
The hybridization was performed at +42ºC for 18 h in hybridization solution (50% formamide, 1M 
NaCl, 1% SDS, 5x Denhardt’s solution, 10% dextran sulphate and 100µg/ml herring sperm DNA). 
The filters were washed three times with 0.1% SDS in 2x SSC at +22ºC and twice with 0.1% SDS 
in 0.2 SSC at +55ºC. The bound probe was detected by autoradiography at -70ºC using Kodak X-
omat films (Eastman Kodak Company, NY, NY, USA). The films were developed and scanned. 
The band intensities were measured with computer densitometry (Bio Image Intelligent Quantifier, 
B. I. Systems Corp. Ann Arbor, MI, USA). The amount of the detected mRNA for CTGF, proα1 I 
collagen, proα1 III collagen and TGFβ1 were calculated in relation to the expression of GAPDH 
mRNA of the corresponding sample. 
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4.7.3 Reverse transcriptase-polymerase chain reaction (RT-PCR) assay for CTGF mRNA
The RNA was extracted from the whole hearts (II, III) and right ventricle (II) with Trizol reagent 
(Gibco Life Technologies, Invitrogen Corporation, Paisley, UK), according to the instructions of the 
manufacturer. After extraction, a 1 µg aliquot of the total RNA was treated with DNAase 1 
(Deoxyribonuclease 1, Sigma Chemical Co., USA) and reverse-transcribed to cDNA by incubation 
for 50 minutes at +45ºC in the presence of reverse transcriptase (Enhanced Avian HS RT-PCR kit, 
Sigma Chemical Co., USA). 2 µl of cDNA was subjected to a quantitative real time polymerase 
chain reaction (PCR) by Lightcycler Instrument (Roche Diagnostics, Neuilly sur Seine, France) for 
the detection of the CTGF mRNA and GAPDH mRNA. The samples were amplified using 
FastStart DNA Master SYBR Green 1 (Roche Diagnostics) in the presence of forward and reverse 
primers (Sigma Genosys, London, UK). After amplification the quality of the PCR products was 
analyzed and the quantities of the CTGF and GAPDH PCR products were quantified with an 
external standard curve amplified from a purified PCR product. 
4.8 IMMUNOHISTOCHEMISTRY
Cryosections (5 µm) were treated with acetone (10 min at -20°C), chloroform (30 min at room temp 
(RT)) and air-dried. Primary antibodies (mouse anti-rat ED1 (Study II, III) ED2 (Study II), CD4 
(Study II, III), CD8 (Study II, III) (Serotec Ltd, Oslo, Norway), anti-rat CTGF (for paraffin 
sections) (Study II, IV) (Abcam, Cambridge, UK) and anti-mouse PCNA (Study II) (Stressgen 
Biotechnologies Corp. Victoria, BC Canada), were applicated for 30 min at RT. The slides were 
then treated with secondary antibody (peroxidase-conjugated rabbit anti-mouse immunoglobulins; 
DAKO A/S, Glostrup, Denmark) for 30 min at RT. After treatment with the third antibody (HRP-
F(ab´)2 goat anti-rabbit (Zymed, SF, CA, USA) for 30 min at RT, the reaction was made visible by 
an AEC (3-amino-9-ethyl carbazole) solution containing hydrogen peroxidase. Finally, the samples 
were counterstained with hematoxyline and mounted. From the processed cardiac samples, the 
amount of the CTGF positive label was scored from 0 to 4 by using a light microscope (IV). From 
the renal samples, the whole cortical and medullary area was photographed and the relative amount 
of primary antibody positive label per sample was determined with computerized densitometry 
(Leica IM500 and Leica QWIN software; Leica Microsystems AG, Heerbrugg, Switzerland). 
In situ detection of DNA fragmentation (Study II) was made by the TUNEL method according to 
the procedures in Apoptosis Detection Kit (Apoptag Peroxidase in Situ Apoptosis Detection Kit, 
Intergen Company, Oxford, UK). In brief, the cardiac and renal sections (5µm) were deparaffinized, 
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hydrated and treated with proteinase K. Endogenous peroxidase was quenched with 3% hydrogen 
peroxide. Terminal deoxynucleotidyl transferase (TdT) enzyme was applied on the specimens and 
incubated at +37°C for one hour. The sections were labeled with an anti-digoxigenin conjugate and 
developed with a peroxidase substrate. Finally, the slides were counterstained with hematoxyline, 
dehydrated and mounted. The degree of apoptosis was measured by counting the number of the 
apoptotic cells (excluding the leukocytes) in 10 high-powered fields for each slide. 
4.9 BIOCHEMICAL DETERMINATIONS 
Urinary protein concentration (I) was measured by the Lowry method (Lowry et al., 1951). 
Urinary albumin concentration (II-IV) was measured by ELISA, using rat albumin as a standard 
(Celltrend GmbH, Luckenwalde, Germany). 
Serum lactate dehydrogenase (s-LDH) activity (II) was determined by UV-kinetic analysis (Hitachi 
912, United Laboratories, Helsinki, Finland). 
Serum ionized magnesium [S-Mg2+] (IV) was measured with ion-selective electrode (NOVA CRT 
8+ electrolyte analyzer (Nova Biomedical, Waltham, NJ, USA). 
4.10 STATISTICAL ANALYSIS
Statistical analysis was carried out by one-way analysis of variance (ANOVA) supported by the 
Tukey’s test (I) or Fisher’s Least-Significant-Difference test (LSD) (II-IV) for pairwise 
comparisons. The two-way ANOVA for repeated measurements was applied for data consisting of 
repeated observations. The correlation between the SBP and CTGF expression (I) was calculated 
with Pearson’s correlation matrix followed by the two-tailed t-test. The level of statistical 
significance was regarded as P<0.05. The results are expressed as mean ± S.E. mean. The data was 
analyzed by using SYSTAT statistical software (SYSTAT Inc, Evanston, IL, USA). 
4.11 ETHICS OF THE STUDY
The study-protocols were approved by the Animal Experimentation Committee of the Institute of 
Biomedicine, University of Helsinki, Finland. 
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5 RESULTS
5.1 BRIEF SUMMARY OF THE MAIN RESULTS
Study I 
The calcineurin inhibitor cyclosporine induced a marked hypertension, myocardial damage and 
CTGF overexpression in the SHRs on high-sodium diet. The expression of the CTGF correlated 
with blood pressure and was effectively prevented with an ACE inhibitor enalapril and an AT1
receptor antagonist valsartan. 
Study II
Ang II induced marked inflammatory end organ damage and CTGF overexpression in the dTGRs. 
Myocardial expression of the CTGF increased in a time- and blood pressure-dependent manner and 
located in the myocardial structures affected by increased inflammatory response and pressure-load. 
Treatment with an immunosuppressant cyclosporine and an AT1 receptor antagonist valsartan 
protected against the Ang II-induced inflammatory response and CTGF overexpression thus 
showing the importance of the Ang II and calcineurin signaling in the regulation of the CTGF gene. 
Study III
Ang II induced severe inflammatory end organ damage, activation of the redox-sensitive 
transcription factors (NF-κB, AP-1) and CTGF overexpression in the dTGRs. The Ang II-induced 
infiltration of inflammatory cells, activation of inflammatory mediators NF-κB and AP-1 as well as 
the overexpression of the CTGF was effectively prevented by suppression of the oxidative stress 
with the antioxidant ?-lipoic acid. 
Study IV 
The Ang II-induced inflammatory end organ damage and CTGF overexpression in the dTGRs was 
prevented with concomitant dietary magnesium supplementation. A calcineurin inhibitor tacrolimus 
produced similar beneficial effects as cyclosporine in the Study II. Magnesium supplementation also 
improved the therapeutic effects of the tacrolimus, which produced marked hypomagnesemia when 
given as monotherapy. 
43
5.2 BLOOD PRESSURE AND CARDIAC HYPERTROPHY
In the SHRs on high-sodium diet (I), CsA (5 mg/kg/d) produced a marked hypertensive effect 
during the six-week treatment period. Concomitant enalapril and valsartan treatment antagonized 
the hypertensive effect of the CsA. CsA tended to further promote LVH but the difference did not 
reach statistical significance (P=0.098). Enalapril and valsartan protected against the development 
of LVH. 
During the three-week experimental periods, untreated dTGRs developed a marked hypertension 
and cardiac hypertrophy compared to the age-matched normotensive SD rats (II-IV). Valsartan 
treatment (II) normalized blood pressure and cardiac hypertrophy in the dTGRs. Calcineurin 
inhibitors CsA (2 mg/kg/d) and tacrolimus (II, IV) produced a modest decrease in blood pressure 
and cardiac hypertrophy. Dietary magnesium had a slight antihypertensive effect (IV) with a 
decrease in the cardiac weight-to-body weight ratio. In contrast, combination treatment with 
tacrolimus and magnesium (IV) normalized blood pressure and ameliorated cardiac hypertrophy. 
Treatment with lipoic acid (III) had a mild antihypertensive effect without a significant reduction in 
cardiac hypertrophy. Mammalian TOR inhibition by everolimus (II) had no effect on blood pressure 
or cardiac hypertrophy in the dTGRs. 
5.3 URINARY PROTEIN EXCRETION
Urinary protein (I) or albumin (II-IV) was measured as an index of the renal damage. 
In the SHRs on high sodium diet, CsA caused a marked proteinuria which was 3.5-fold higher than 
in the control group. In addition, CsA treatment resulted in an elevated level of serum creatinine and
a decline in a creatinine clearance. Antagonism of the RAS with enalapril or valsartan prevented the 
increase in the urinary protein excretion. Nevertheless, despite the treatments, the urinary protein 
excretion in the SHRs remained at a higher level than usually seen in their normotensive counter 
parts, Wistar Kyoto rats. 
The dTGRs developed a marked albuminuria, which was from 20 to 150-fold higher than in the SD 
rats (II-IV). The AT1-receptor antagonist valsartan, as well as CsA, tacrolimus (alone or combined 
with magnesium) and lipoic acid (II-IV) protected against the development of albuminuria 
effectively, whereas everolimus (II) had a less marked effect. In contrast, magnesium treatment did 
not have an effect on the urinary albumin excretion. 
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5.4 HISTOPATHOLOGY 
5.4.1 Myocardial lesions
In the SHRs receiving high sodium diet (I), every ventricular sample had pathological alterations. 
The majority of the epicardial and intramuscular arteries showed adventitial scarring, medial 
thickening and smooth muscle cell vacuolization. The ventricular muscle had patches of thin 
fibrotic scars and signs of recent infarcts. The lesions in the CsA (5 mg/kg/d) group were more 
severe than in the control group. The epicardial and intramuscular arteries manifested marked 
adventitial fibrosis, varying degrees of medial thickening and smooth muscle cell vacuolization. 
Also the number and area of the observed myocardial scars exceeded those seen in the control 
group. The cardiac damage index value did not differ significantly between the control and CsA 
groups. In contrast, the cardiac damage index value was markedly lower with the higher dose of 
valsartan when compared to the CsA group. 
Treatment with the ACE inhibitor enalapril or the lower dose of the angiotensin AT1 receptor 
antagonist valsartan prevented the development of the CsA-induced pathological alterations, 
whereas the higher dose of valsartan seemed to be even more beneficial. 
The hearts of the untreated dTGRs (II-IV) showed severe pathological alterations. The epicardial 
and intramuscular arteries had perivascular inflammation, adventitial scarring, medial thickening 
and sometimes fibrinoid necrosis. The intramuscular arteries showed marked medial/intimal 
hyperplasia (concentric hypertrophy) leading to vessel occlusion. The ventricular muscle had 
patches of fibrotic scars and signs of recent infarcts with inflammation. Cell proliferation as well as 
apoptosis was increased in the hearts of the untreated dTGRs. Treatment with the AT1 receptor 
antagonist valsartan (II) prevented the Ang II-induced morphological damage in the heart. 
Calcineurin inhibition with CsA (2 mg/kg/d) (II) had no major effect on the cardiac morphology. 
Although CsA protected against the Ang II-induced inflammation, cell proliferation, apoptosis and 
myocardial infarcts, arteries were still notably affected. Interestingly, calcineurin inhibitor 
tacrolimus (IV) had an evident cardioprotective effect. Lipoic acid (III) effectively prevented Ang 
II-induced vascular lesions and myocardial infarcts. Treatment with magnesium alone (IV) had a 
slight cardioprotective effect, whereas combination treatment with tacrolimus provided a very  
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effective inhibition against the Ang II-induced myocardial lesions. Interestingly, myocardial 
damage tended to worsen by everolimus (II). Everolimus treatment caused numerous infarcts with a 
marked accumulation of monocytes/macrophages. Intramuscular and epicardial arteries were 
notably thickened and had areas of fibrinoid necrosis and perivascular inflammation.
5.4.2 Renal lesions
The description of the renal histopathology in the Study I has been previously published (Lassila et 
al., 2000). In the SHRs on high sodium diet (I), there were minor pathological alterations involving 
a small portion (4%) of the glomeruli. Neither tubular nor interstitial changes were detected. In 
contrast, in the CsA group one-third of the glomeruli were apparently damaged. Within the affected 
glomeruli, the pathological changes varied from a slight mesangial matrix expansion to a severe 
necrosis and capillary collapse. Interstitial fibrosis of striped pattern was also found in the cortical 
areas of the CsA-treated SHRs. Tubular atrophy and dilatation located in the tubuli surrounded by 
fibrotic tissue. The large renal arteries in the CsA group were mostly normal, only a slight 
thickening of the adventitia was found, whereas smaller arteries had medial changes ranging from a 
minor smooth muscle cell vacuolization to a massive smooth muscle and endothelial cell 
proliferation. All the CsA-induced pathological changes were completely prevented by blocking the 
RAS with enalapril or valsartan (Lassila et al., 2000). 
The kidneys of the untreated dTGRs (II-IV) had severe histopathological changes as indicated by 
the increased renal damage index. The damage in the glomeruli ranged from a slight mesangial 
expansion to a capillary collapse, glomerular sclerosis or necrosis. The intrarenal arteries had 
varying degrees of medial/intimal hyperplasia and fibrinoid necrosis of the vessel wall. There was 
marked perivascular and periglomerular inflammation characterized by an abundance of ED1, ED2, 
CD4 and CD8 immunopositive cells. In addition, the redox-sensitive intracellular mediators of 
inflammation, NF-κB and AP-1 were activated in the dTGRs (II). The tubules were affected to a 
minor extent. Some tubuli were atrophied or dilated when surrounded by interstitial fibrotic tissue. 
Part of the tubuli were necrotic or had peritubular fibrosis with inflammation. The Ang II-induced 
cellular apoptosis located primarily in the epithelium of the proximal tubules. Valsartan, CsA, 
tacrolimus and lipoic acid (II-IV) prevented the Ang II-induced renal damage efficiently, whereas 
magnesium (IV) had lesser effect. The combination treatment with magnesium and tacrolimus 
produced a very effective protection against the Ang II-induced renal damage. Although everolimus 
partially prevented the development of albuminuria in the dTGRs (II), it still increased the amount 
and severity of the renal damage in the dTGR. Lesions of the intrarenal arteries were similar but 
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more severe than in the dTGR group. Proximal tubules had necrosis and apoptosis. Patches of 
interstitial fibrosis and ED1/ED2 positive inflammatory cells were seen throughout the sample. 
However, everolimus partially attenuated the T cell-mediated inflammatory response, and cell 
proliferation in the kidneys. 
5.5 EXPRESSION OF CTGF
5.5.1 Myocardial expression of CTGF
In the SHRs (I), in situ hybridization showed a minor CTGF mRNA positive label in the epicardial 
artery media where it was expressed by a small number of smooth muscle cells. There was a faint 
CTGF expression in the ventricular fibrotic scars. CTGF mRNA expression was markedly 
upregulated in the arterial media of the CsA group, where the positively labeled cells had the 
phenotype of a smooth muscle. Equally to the control group, the CTGF positive label was detected 
mostly in the vascular media, and in the extensive ventricular scars. Concomitant treatment with 
enalapril and the lower dose of valsartan prevented the increment in CTGF mRNA expression, 
whereas treatment with the higher dose of valsartan reduced CTGF expression by 75% compared to 
the control group, and by 85% compared to the CsA-treated SHR on high sodium diet. When the 
expression of the myocardial CTGF mRNA was compared between the 14-week-old hypertensive 
SHR rats and the age-matched normotensive WKY rats on low-sodium diet, we noticed a strain-
specific induction of the CTGF mRNA in the SHRs. 
In the untreated dTGRs (II-IV), as detected with in situ hybridization, immunohistochemistry and 
Northern blot, CTGF mRNA and protein expression was markedly up-regulated especially in the 
arterial media. A strong CTGF mRNA expression was also detected in the inflamed areas of the 
vasculature and muscle. The fibrotic scars and infarcts of the ventricle had a strong CTGF mRNA 
positive label in the outer boundaries (fresh infarct) or throughout the area (scar) of the lesion. In 
the SD group, a faint CTGF mRNA expression was detected in the media of epicardial and 
intramuscular arteries. In the ventricular muscle only a few positively labeled cells were noted. 
Valsartan, CsA, tacrolimus, lipoic acid (0.047±0.018 vs. 0.2±0.049; P=0.002; n=6) and magnesium 
(II-IV) prevented the Ang II-induced CTGF gene expression completely, whereas everolimus 
treatment (II) had no effect on the CTGF expression.
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5.5.2 Renal expression of CTGF
In the kidneys of the dTGRs (II), CTGF mRNA and peptide expression located mainly in the renal 
corpuscles, arteries and in the interstitium. There was a marked up-regulation of the CTGF mRNA 
expression in the media of the arcuate, interlobular and afferent arteries. Also, an enhanced 
expression was detected in the interstitial and glomerular areas with inflammation, necrosis or 
fibrosis. The SD group had a slight CTGF mRNA positive signal mainly in the same areas as in the 
dTGR rats. However, there was no detectable signal in the tubules or interstitium, whereas a diffuse 
signal was expressed in the vascular media. Treatment with valsartan and CsA protected effectively 
against the Ang II-induced increase in CTGF mRNA. Treatment with everolimus (II) resulted in an 
opposite effect. It further increased the expression of the renal CTGF mRNA. 
5.5.3 Time- and blood pressure-dependent expression of CTGF
In the SHRs (I), we noticed a close correlation between the systolic blood pressure and myocardial 
CTGF expression. 
The expression of the myocardial CTGF mRNA was similar in the juvenile (3-4 week-old) dTGRs 
and SD rats (II). Both in the heart and kidneys of the dTGRs, the temporal expression of the CTGF 
mRNA revealed a strong up-regulation in the gene expression at the onset of hypertension between 
the postnatal weeks 4 and 5.5. The difference in CTGF mRNA expression between the weeks 5.5 
and 7 was less pronounced. At the age of 7 weeks, CTGF mRNA expression in the heart and 
kidneys of the untreated dTGRs was 3.5 and 1.65 -fold higher as compared to the normotensive SD 
rats, respectively. 
To further elucidate the role of blood pressure as a regulator of the CTGF expression, also low-
pressure cardiovascular structures (right ventricle, pulmonary artery) were examined. The 
expression of the CTGF mRNA in the right ventricle of the 7-week-old SD and dTGRs indicated a 
noticeable but not significant increase in the amount of the CTGF mRNA in dTGR. In the 
pulmonary arteries of the SD and dTGRs the CTGF mRNA positive signal was almost absent, 
indicating no differences between these groups. 
The main findings and effects of treatment with different compounds in corresponding animals are 
summarized in Table 2. 
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6 DISCUSSION
The hypertension-induced end organ damage predisposes the hypertensive patients to numerous 
cardiovascular complications leading to premature disability and mortality. The deterioration of the 
cardiovascular and renal function results partly from the pathologic inflammatory reaction and 
connective tissue accumulation occurring also by blood pressure-independent mechanisms. 
Although the research has today focused to explore the role of locally acting growth factors and 
mediators of connective tissue formation, the exact mechanisms contributing to the hypertension–
induced inflammatory end organ damage remain still more or less obscure. 
This study investigated the role of the CTGF in the pathogenesis of hypertension-induced end organ 
damage in two hypertensive animal models with increased RAS activity: CsA-treated SHRs on high 
sodium diet and dTGRs. As regulators of the CTGF expression, the participation of the increased 
blood pressure and Ang II were studied. 
6.1 METHODOLOGICAL ASPECTS
6.1.1 Increased RAS activity in SHR and dTGR 
The SHR is the most widely used animal model for human hypertension. The SHR is an inbred 
strain which develops hypertension and its complications with increasing age. Although criticized 
as being an inappropriate model for human hypertension, the arterial hypertension in the SHR and 
essential human hypertension share many similarities in the pathogenic mechanisms (Trippodo and 
Frohlich, 1981). To examine the pathogenesis of the CsA-induced hypertension and end organ 
damage, we have developed an animal model for CsA toxicity, i.e. the CsA-treated SHR on high 
sodium diet (Mervaala et al., 1997). This animal model expresses increased RAS activity and 
develops hypertension and renal lesions similar to CsA-treated humans (Mervaala et al., 1997; 
Lassila et al., 2000). Importantly, the development of hypertension and nephrotoxicity is achieved 
by using an adequate drug dosage (CsA 5mg/kg/d) producing therapeutically high, but relevant 
blood concentration (750 ng/ml) (Mervaala et al., 1997). 
Previously, majority of the experimental studies focusing on the pathogenesis of CsA toxicity were 
conducted in normotensive rats receiving either normal chow with sodium concentration 
approximately 0.25-0.3 % w/w, or sodium-depleted diet (Burdmann et al., 1995; Shihab et al., 
1999). In these animal models a fairly high CsA dosage (usually 15 mg/kg/d producing  
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blood CsA concentrations of 5000-6000 ng/ml) causes renal damage similar to that found in the 
CsA-treated patients (Shihab et al., 1999). However, even though CsA induces pronounced renal 
damage in these animal models, the rats usually remain normotensive. Therefore these animal 
models are not very suitable for studying the mechanisms of CsA-induced hypertension. 
In experimental rat models CsA increases PRA regardless of the sodium content of the diet 
(Burdmann et al., 1995; Mervaala et al., 1997). Although the administration of CsA in humans is 
usually associated with volume-expanded, low renin form of hypertension, CsA has also been 
reported to elevate PRA in cardiac and liver transplant patients and plasma Ang II levels in patients 
with psoriasis (Julien et al., 1993; Edwards et al., 1994). Since the clinical CsA treatment in 
humans is partly limited by the drug-induced hypertension and nephrotoxicity, and the CsA-induced 
hypertension has been shown to depend on the level of dietary salt (Curtis et al., 1988; Textor et al., 
1994), we believe that our animal model provides valuable information when studying the CsA-
induced hypertension and its associated complications. 
The dTGR was originally developed for studying human renin inhibitors which ordinarily do not 
function in rats. The human components of RAS in the dTGR do not interact with the endogenous 
rat RAS (Ganten et al., 1992; Bohlender et al., 1997). Hypertension, vascular inflammation and end 
organ damage in the dTGR are due to increased Ang II synthesis by the human components of the 
RAS. Ang II concentrations in the circulation and in the tissues are about 3 to 5-fold higher in the 
dTGR compared to non-transgenic SD controls (Mervaala et al., 2000b). Therefore, the dTGR can 
be considered as an appropriate model for studying the Ang II-induced pathologic effects on blood 
pressure and end organ structure/function. 
6.1.2 Blood pressure measurements
In the present study, blood pressure was measured indirectly by the tail-cuff method. When a study 
design requires monitoring of a large number of animals, the non-invasive tail-cuff method is 
commonly chosen. The advantage of this method is its relative simplicity and low cost compared to 
e.g. the radiotelemetric method. Tail-cuff recording correlates well with direct blood pressure 
recordings where intra-arterial catheters are used (Bunag and Butterfield, 1982). However, tail-cuff 
recording may overestimate the real blood pressure levels possibly affected by ambient temperature, 
restrainers, smells, noise, and the tail-cuff itself. To minimize the stress-inducing stimuli, the blood 
pressure measurements in the present study were performed on pretrained rats by the same person 
in a quiet and peaceful environment. 
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6.2 EFFECT OF BLOOD PRESSURE ON CTGF EXPRESSION 
In the present study, we noticed a close correlation between the systolic blood pressure and 
myocardial CTGF expression in the SHRs. The CsA-treatment (5 mg/kg/d) produced a malignant 
hypertension with marked end organ damage without an inflammatory component. In addition to 
elevated mechanical strain, the induction of the CTGF in CsA-treated SHRs could have also been a 
consequence from other, yet unresolved events, like hypoxia or production of the ROS (Nishiyama 
et al., 2003). 
Next, the effect of blood pressure on the CTGF mRNA expression was examined more closely by 
using the dTGRs. Although the expression of the myocardial CTGF mRNA was similar in 3-4 
week-old SD and dTGR rats, a marked up-regulation of the myocardial and renal CTGF gene 
expression in the dTGRs occurred between the postnatal weeks 4 and 5.5, and to a lesser extent 
between the weeks 5.5 and 7. We noticed that the up-regulation of the CTGF gene occurred at the 
onset of Ang II-induced hypertension before an overt myocardial and renal damage was observed. 
For a further evaluation of the blood pressure-dependent expression of the CTGF, cardiac structures 
not affected by the systolic blood pressure (right ventricle, pulmonary artery) were examined. The 
CTGF mRNA level in the right ventricle of the 7-week old dTGRs was noticeably but not 
significantly higher than in the SD rats.  
Furthermore, when we examined the expression of the CTGF mRNA in the pulmonary arteries of 
the dTGRs and SDs, there was no notable difference between these two rat strains. The CTGF 
mRNA positive signal was almost completely absent from all the samples studied, which is in 
contrast to the marked difference we have noted in the CTGF mRNA expression between the 
myocardial arteries in the dTGR and SD. 
Although it is difficult to separate the effects of hemodynamic and humoral factors in an in vivo
model, there are several reports which propose increased mechanical stress as an inducer of the 
CTGF and connective tissue synthesis. In vitro studies have revealed that static and cyclic stress 
enhances the expression of the CTGF (Riser et al., 2000; Hishikawa et al., 2001). The pathways by 
which the induction of the CTGF is regulated in the conditions above remain obscure. The recently 
discovered stretch-responsive element in the CTGF promoter region might be involved in the 
regulation of the CTGF under mechanical stimuli. Previously, a mechanical strain-responsive 
element has been found in the rat collagen I gene and the induction of collagen III gene has been 
noted in association of cyclic mechanical stretch (Carver et al., 1991; Lindahl et al., 2002). 
Furthermore, the studies by van Wamel et al. (2002) have shown that TGFβ1 mRNA expression in 
stationary cardiomyocytes is increased by the release of Ang II from stretched cardiomyocytes. 
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6.3 EFFECT OF ANG II AND INFLAMMATORY RESPONSE ON CTGF EXPRESSION
Wound heals through inflammation and connective tissue formation. An exception can be seen in 
the early phases of embryonic development when there is no inflammatory response to an injuring 
stimulus. The healing occurs by the proliferation of the cells surrounding the lesion and no fibrosis 
occurs. Interestingly, in the early embryonic stage CTGF participates in the organogenesis, and 
even injected CTGF mRNA does not promote fibrosis, but instead it results in an abnormal 
differentiation of embryonic structures (Abreu et al., 2002). 
In several studies, the up-regulation of the CTGF expression has been noted in conjunction with 
inflammatory lesions. Induction of the CTGF has been shown in the inflammatory diseases of 
kidneys, lungs, liver, pancreas, skin, cardiovascular system, and colon (Table 1). Besides having an 
inflammatory component, characteristic of these diseases is also an abnormal homeostasis of 
connective tissue. The difficulty in auto-immune diseases is the prolonged state of inflammation 
and activity of fibrosis-promoting growth factors, which does not seem to serve any physiological 
function. This “inflammation-wound healing” occurs without previous traumatic episode and reacts 
to the organisms own molecules as hostile invaders.
The participation of the RAS and Ang II in the processes of inflammation-connective tissue 
formation has been clearly demonstrated. Besides acting as a circulating humoral system, RAS 
operates also locally. The local RAS is particularly active in atherosclerotic arteries in which 
increased expression of the ACE and AT1 receptor can be seen in the inflammatory cells of 
atherosclerotic plaques (Fukuhara et al., 2000; Gross et al., 2002). In numerous experimental 
studies, it has been noted that hindering the activity of RAS, either with ACE inhibitors or AT1
receptor antagonists, protects against the Ang II-induced NF-κB-mediated neointimal inflammation 
in atherosclerosis, NF-κB-mediated inflammation of the renal cortex, inflammatory experimental 
glomerulonephritis and diabetic nephropathy (Morrissey and Klahr, 1997; Hernandez-Presa et al., 
1998; Ruiz-Ortega et al., 1998; for review, see Schiffrin, 2002b).  
Hypertension, vascular inflammation and end organ damage in the dTGR are due to increased Ang 
II synthesis by the human components of the RAS (Mervaala et al., 2000b). In the dTGRs, marked 
inflammatory cell recruitment, mainly consisting of monocytes and macrophages, as well as the up-
regulation of the adhesion molecules VCAM-1, ICAM-1, and the extracellular matrix component 
fibronectin, are already present immediately after weaning (Mervaala et al., 1999; Müller et al., 
2000b). The interpretation made from these findings is that Ang II triggers inflammatory response 
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and exerts direct pro-inflammatory effects even by blood pressure-independent mechanisms related 
to the activation of the redox-sensitive transcription factors NF-κB and AP-1, as well as oxidative 
stress. 
In the present study, we showed that in the dTGRs, the expression of the myocardial CTGF mRNA 
was markedly up-regulated in the vascular media and in the inflamed and infarcted areas. Induction 
of the renal CTGF mRNA was located mainly in the medial layer of the arteries, in the interstitium 
and in the necrotic glomeruli. Both in the heart and kidneys, the expression of the CTGF co-located 
very closely with infiltrated leukocytes suggesting an important role for inflammatory response in 
the CTGF gene regulation. Furthermore, we noticed that the induction of the CTGF in the dTGRs 
was associated with the concomitant activation of inflammatory mediators NF-κB and AP-1. In 
contrast, in the CsA-treated (5 mg/kg/d) SHRs on high sodium diet, we did not notice any signs of 
myocardial inflammation. Despite the lack of the visible inflammation in this model, there were 
numerous scars in the myocardium indicating previous phases of reparative fibrosis and presence of 
leukocytic cells. In addition, the contribution of the NF-κB and AP-1 in regulating the gene 
expression of the CTGF in the CsA-treated SHR can be proposed on the basis of the recent findings 
by Asai et al. (2003), who showed that chronic CsA-treatment in rats promotes the activity of the 
AP-1 and NF-κB. The 50-fold increment in the observed plasma renin activity of the CsA group 
compared to the group receiving vehicle, proposes the involvement of the RAS in regulating the 
expression of the CTGF. It has been previously reported that CsA stimulates RAS and up-regulates 
Ang II receptors in human vascular smooth muscle cells (Avdonin et al., 1999; for review, see 
Lassila, 2002). Furthermore, high sodium diet has also been shown to promote cardiac ACE activity 
in rats (Kreutz et al., 1995). The role of the RAS in regulating CTGF can be further proposed by the 
presence of the NF-κB, AP-1 and TGFβ1 regulatory elements in the CTGF gene promoter region. 
Besides stimulating the activity of the NF-κB and AP-1, Ang II induces fibrosis in the heart and 
kidneys through TGFβ1 (Everett et al., 1994; Dostal, 2001). In the dTGRs, by using in situ
hybridization CTGF mRNA was noticed to co-locate very closely with TGFβ1 mRNA. This 
suggests also the involment of the TGFβ1 as a regulator of the CTGF in this model. However, the 
induction of the TGFβ1 occurred only in the kidneys of the dTGRs. Therefore, further studies would 
be required to determine the role of the TGFβ1 as a regulator of the CTGF gene expression in this 
model. 
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In the present study, the regulation of the CTGF expression seemed to involve the following Ang II 
dependent pathways:  
1. Ang II signaling through the AT1 receptor appeared to be involved as the expression of the CTGF 
was markedly decreased by valsartan in the dTGRs and CsA-treated SHRs. In the SHRs, treatment 
with valsartan resulted in a lower CTGF expression than could have been presumed from its 
antihypertensive effect. This supports the findings by Candido et al. (2002) who demonstrated a 
marked vascular CTGF overexpression and ACE activity in diabetic apolipoprotein-E knock-out 
mice. ACE inhibitor therapy inhibited the development of atherosclerotic lesions and diabetes-
induced ACE and CTGF overexpressions in the aorta. 
2. In the dTGRs, ROS seemed to be involved in the regulation of the CTGF gene, as the treatment 
with antioxidant lipoic acid hindered the activity of the redox-sensitive NF-κB and AP-1, and 
prevented the induction of the CTGF gene. Ang II stimulates NADPH oxidase to produce ROS, 
which participate in the regulation of the VSMC growth, induction of vascular inflammatory 
response, impairment of endothelial-dependent vascular relaxation, pathogenesis of cardiac 
hypertrophy and stimulation of the CTGF expression (Griendling et al., 2000; Park et al., 2001). 
3. In the present study, the Ang II-stimulated activation of the T cell calcineurin phosphatase 
seemed to be involved in the Ang II-induced expression of the CTGF in dTGRs, as the blockade of 
the calcineurin activity with CsA or tacrolimus protected against the inflammatory response and up-
regulation of the CTGF mRNA. Previously, it has been shown that human T cells synthesize CTGF 
and Ang II promotes the proliferation and function of T cells via calcineurin dependent pathway 
(Nataraj et al., 1999; Workalemahu et al., 2003). Nataraj et al. (1999) also found that calcineurin 
inhibition completely blocked the ability of the Ang II to induce proliferation of the cultured splenic 
lymphocytes, demonstrating that calcineurin is required for the stimulation of the lymphocyte 
proliferation by AT1 receptors. Increased activity of the calcineurin has been connected to other 
adverse events e.g. cardiac hypertrophy, heart failure, overexpression of the TGFβ1, activation of 
the NF-κB, and organ transplant rejection (Molkentin et al., 1998; Molkentin and Dorn, 2001). In 
our previous studies it was noted that, in dTGRs, Ang II induces inflammation even by blood 
pressure-independent mechanisms and the inflammation with the subsequent end organ damage can 
be prevented with calcineurin inhibition. (Mervaala et al., 2000a; Mervaala et al., 2000b). 
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4. The redox-sensitive mediators of inflammation, NF-κB and AP-1 probably mediated the final, 
DNA-binding step in the CsA-treated SHRs and in the dTGRs. This could be proposed by the 
presence of the NF-κB and AP-1-binding elements in the CTGF gene promoter region. To support 
this speculation, a marked activation of the NF-κB and AP-1 was noticed in dTGRs. Treatment with 
antioxidant lipoic acid resulted in a diminished activity of the NF-κB, AP-1, and suppression of the 
CTGF gene expression. Furthermore, in the dTGRs, magnesium supplementation, which has been 
shown to diminish the activation of the AP-1 and NF-κB, protected against the induction of the 
CTGF gene (Asai et al., 2003). Although controversial data exist, NF-κB and AP-1 are today 
considered as positive regulators of the CTGF expression (Blom et al., 2002). 
6.4 POSSIBLE CLINICAL IMPLICATIONS 
Currently, ACE inhibitors, AT1 receptor antagonists, and statins are widely used to prevent the 
cardiovascular end organ damage in arterial hypertension. Besides having anti-hypertensive or 
LDL-lowering effects, these drugs have been shown to diminish the accumulation of adverse 
connective/scar tissue in the heart, kidney and vasculature. Despite the various beneficial effects of 
the aforementioned drugs, the antifibrotic therapy could also be targeted on a single molecule. 
Previous expectations focused on TGFβ1, which has a central role in connective tissue synthesis. 
Unexpectedly, studies with anti-TGFβ1 antibody and TGFβ1-knockout mice have revealed the 
importance of the TGFβ1 as a controller of growth and inflammation. In numerous experimental 
studies, inhibition of the TGFβ1-signaling has resulted in hyperinflammation, atherosclerosis, and 
malignancies (Murphy et al., 1999; Mallat et al., 2001; Engle et al., 2002). CTGF is induced by 
various components of injuring conditions (high glucose, mechanical strain and inflammation) and 
the presence of the CTGF in tissue samples and body fluids has been shown to correlate with the 
degree of diabetic nephropathy and other fibrotic processes (Tamatani et al., 1998; Sato et al., 2001; 
Riser et al., 2003). Whether CTGF mediates the immunomodulatory or anti-carcinogenic effects of 
the TGFβ1 is not yet known. Acting as a downstream mediator of the TGFβ1-induced collagen 
production, CTGF may provide a more selective drug target in anti-fibrotic therapy. The blockade 
of the CTGF may thus avert the possible dangers associated with the antagonism of the TGFβ1. 
On the basis of recent investigations CTGF has a potential of serving as a suitable drug target or an 
early marker of various inflammatory/fibrotic disease states and a reliable indicator of response to 
therapy. 
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7 SUMMARY AND CONCLUSIONS 
This study investigated the expression of the CTGF in the pathogenesis of the hypertension-induced 
end organ damage by using two hypertensive animal models with increased RAS activity: the CsA-
treated SHR on high sodium diet and the dTGR. 
The main findings and conclusions are as follows: 
• Arterial hypertension induced myocardial CTGF mRNA expression. 
• In the dTGRs, Ang II induced CTGF expression in a time- and blood pressure-dependent 
manner primarily via AT1 receptor stimulation. Ang II-induced CTGF overexpression was 
linked to increased oxidative stress and inflammatory response of the vascular wall. 
• Blockade of the RAS activity either with the ACE inhibitor or the AT1 receptor antagonist 
prevented the overexpression of the CTGF gene. 
• Calcineurin inhibitors CsA and tacrolimus as well as the antioxidant lipoic acid effectively 
protected against the induction of the CTGF gene in the dTGR. 
• Magnesium supplementation reduced the Ang II-induced myocardial damage and CTGF 
overexpression. Additive therapeutic effects were found with magnesium supplementation
and calcineurin inhibitor.
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